{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:51:05Z","timestamp":1793321465946,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier","isbn-type":[{"value":"9780443186677","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.irn.2023.08.001","type":"book-chapter","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T19:20:36Z","timestamp":1692991236000},"page":"1-27","source":"Crossref","is-referenced-by-count":8,"title":["A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists"],"prefix":"10.1016","author":[{"given":"Kenneth A.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Rama","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.irn.2023.08.001_bib1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainres.2007.11.051","article-title":"CSC, an adenosine A2A receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats","volume":"1191","author":"Aguiar","year":"2008","journal-title":"Brain Research"},{"issue":"7","key":"10.1016\/bs.irn.2023.08.001_bib2","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1021\/acs.jmedchem.0c01856","article-title":"Crystal structure and subsequent ligand design of a nonriboside partial agonist bound to the adenosine A2A receptor","volume":"64","author":"Amelia","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"10","key":"10.1016\/bs.irn.2023.08.001_bib3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1021\/cn5001606","article-title":"JNJ-40255293, a novel adenosine A2A\/A1 antagonist with efficacy in preclinical models of Parkinson's disease","volume":"5","author":"Atack","year":"2014","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.irn.2023.08.001_bib4","doi-asserted-by":"crossref","unstructured":"Baraldi, S., Baraldi, P. G., Oliva, P., Toti, K. S., Ciancetta, A., Jacobson K. A. (2018). Chapter 5. A2A adenosine receptor: Structures, modeling and medicinal chemistry. In K. Varani (Vol. Ed.), The Adenosine Receptors, The Receptors (pp. 91\u2013136). Springer. https:\/\/doi.org\/10.1007\/978-3-319-90808-3_5.","DOI":"10.1007\/978-3-319-90808-3_5"},{"issue":"5","key":"10.1016\/bs.irn.2023.08.001_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1124\/mol.112.084509","article-title":"Isolated A2A-R conformation pharmacology defines efficacy","volume":"83","author":"Bennett","year":"2013","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2023.08.001_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0033-0620(89)90015-7","article-title":"The cardiac effects of adenosine","volume":"32","author":"Belardinelli","year":"1989","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"15","key":"10.1016\/bs.irn.2023.08.001_bib7","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1021\/jm049947s","article-title":"New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine","volume":"47","author":"Beukers","year":"2004","journal-title":"Journal of Medicinal Chemistry"},{"issue":"12","key":"10.1016\/bs.irn.2023.08.001_bib8","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1021\/acs.jmedchem.6b00552","article-title":"Discovery of 7-(prolinol-N-yl)-2-phenylamino-thiazolo[5,4-d]pyrimidines as novel non-nucleoside partial agonists for the A2A adenosine receptor: Prediction from molecular modeling","volume":"59","author":"Bharate","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.neuropharm.2011.01.048","article-title":"Adenosine hypothesis of schizophrenia\u2014Opportunities for pharmacotherapy","volume":"62","author":"Boison","year":"2012","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2023.08.001_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/biomedicines10020515","article-title":"Ribose and non-ribose A2A adenosine receptor agonists: Do they share the same receptor recognition mechanism?","volume":"10","author":"Bolcato","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/bs.irn.2023.08.001_bib11","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: The state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiological Reviews"},{"issue":"7","key":"10.1016\/bs.irn.2023.08.001_bib12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1021\/jm00402a004","article-title":"N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor","volume":"31","author":"Bridges","year":"1988","journal-title":"Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1016\/bs.irn.2023.08.001_bib13","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1073\/pnas.77.9.5547","article-title":"Adenosine receptors in brain membranes: Binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine","volume":"77","author":"Bruns","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.irn.2023.08.001_bib14","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1200\/JCO.2021.39.15_suppl.2562","article-title":"Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor","volume":"39","author":"Buisseret","year":"2021","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.irn.2023.08.001_bib15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/ph15040478","article-title":"4-Heteroaryl substituted amino-3,5-dicyanopyridines as new adenosine receptor ligands: Novel insights on structure-activity relationships and perspectives","volume":"15","author":"Catarzi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nri.2016.4","article-title":"Purinergic regulation of the immune system","volume":"16","author":"Cekic","year":"2016","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.irn.2023.08.001_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson\u2019s disease.","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signalling"},{"issue":"51","key":"10.1016\/bs.irn.2023.08.001_bib18","doi-asserted-by":"crossref","first-page":"eadd3709","DOI":"10.1126\/sciadv.add3709","article-title":"Cryo-EM structure of the human adenosine A2B receptor\u2013Gs signaling complex","volume":"8","author":"Chen","year":"2022","journal-title":"Science Advances"},{"issue":"5","key":"10.1016\/bs.irn.2023.08.001_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3727\/096368910X491806","article-title":"Adenosine A2A agonist administration improves islet transplant outcome: Evidence for the role of innate immunity in islet graft rejection","volume":"19","author":"Chhabra","year":"2010","journal-title":"Cell Transplantation"},{"issue":"11","key":"10.1016\/bs.irn.2023.08.001_bib20","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-21-2742","article-title":"Phase I study of taminadenant (PBF509\/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab (PDR001), in patients with advanced non-small cell lung cancer","volume":"28","author":"Chiappori","year":"2022","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.irn.2023.08.001_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s42004-023-00894-6","article-title":"Crystal structure of adenosine A2A receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction","volume":"6","author":"Claff","year":"2023","journal-title":"Commun Chem"},{"issue":"16","key":"10.1016\/bs.irn.2023.08.001_bib22","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00018-007-7051-9","article-title":"Caffeine analogs: Biomedical impact","volume":"64","author":"Daly","year":"2007","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"key":"10.1016\/bs.irn.2023.08.001_bib23","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1021\/jm4011669","article-title":"Adenosine A2A receptor as a drug discovery target","volume":"57","author":"de Lera Ruiz","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1016\/bs.irn.2023.08.001_bib24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.str.2011.06.014","article-title":"Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine","volume":"19","author":"Dor\u00e9","year":"2011","journal-title":"Structure (London, England: 1993)"},{"issue":"2","key":"10.1016\/bs.irn.2023.08.001_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pbb.2012.05.001","article-title":"Time and sex-dependent effects of an adenosine A2A\/A1 receptor antagonist on motivation to self-administer cocaine in rats","volume":"102","author":"Doyle","year":"2012","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/bs.irn.2023.08.001_bib26","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.1021\/jacs.8b03805","article-title":"Extrinsic tryptophans as NMR probes of allosteric coupling in membrane proteins: Application to the A2A adenosine receptor","volume":"140","author":"Eddy","year":"2018","journal-title":"Journal of the American Chemical Society"},{"issue":"22","key":"10.1016\/bs.irn.2023.08.001_bib27","doi-asserted-by":"crossref","first-page":"15238","DOI":"10.1021\/acs.jmedchem.2c01170","article-title":"Structure activity studies of 1H-imidazo[4,5-c]quinolin-4-amine derivatives as A3 adenosine receptor positive allosteric modulators","volume":"65","author":"Fallot","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.irn.2023.08.001_bib28","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1021\/cb5005383","article-title":"Uncovering caffeine\u2019s adenosine A2A receptor inverse agonism in experimental parkinsonism","volume":"9","author":"Fern\u00e1ndez-Due\u00f1as","year":"2014","journal-title":"ACS Chemical Biology"},{"issue":"4","key":"10.1016\/bs.irn.2023.08.001_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/caff.2018.0017","article-title":"New developments on the adenosine mechanisms of the central effects of caffeine and their implications for neuropsychiatric disorders","volume":"8","author":"Ferr\u00e9","year":"2018","journal-title":"Journal of Caffeine and Adenosine Research"},{"key":"10.1016\/bs.irn.2023.08.001_bib30","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017009613","article-title":"Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease","volume":"1","author":"Field","year":"2017","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1471-4892(03)00039-0","article-title":"The case for a role for adenosine in asthma: Almost convincing?","volume":"3","author":"Fozard","year":"2003","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1021\/jm00400a022","article-title":"Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists","volume":"31","author":"Francis","year":"1988","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"10.1016\/bs.irn.2023.08.001_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.0954-6820.1985.tb01650.x","article-title":"On the mechanism of action of theophylline and caffeine","volume":"217","author":"Fredholm","year":"1985","journal-title":"Acta Medica Scandinavica"},{"issue":"1","key":"10.1016\/bs.irn.2023.08.001_bib34","first-page":"209","article-title":"Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists","volume":"298","author":"Gao","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2023.08.001_bib35","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0006-2952(03)00153-9","article-title":"N6-Substituted adenosine derivatives: Selectivity, efficacy, and species differences at A3 adenosine receptors","volume":"65","author":"Gao","year":"2003","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib36","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35946","article-title":"Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein","volume":"7","author":"Garc\u00eda-Nafr\u00eda","year":"2018","journal-title":"eLife"},{"key":"10.1016\/bs.irn.2023.08.001_bib37","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fphar.2017.00888","article-title":"Inhibition of A2A adenosine receptor signaling in cancer cells proliferation by the novel antagonist TP455","volume":"8","author":"Gessi","year":"2017","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2023.08.001_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1568026616666160719164207","article-title":"Structure-based rational design of adenosine receptor ligands","volume":"17","author":"Guti\u00e9rrez-de-Ter\u00e1n","year":"2017","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.irn.2023.08.001_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s10194-018-0867-x","article-title":"Characterization of the trigeminovascular actions of several adenosine A2A receptor antagonists in an in vivo rat model of migraine","volume":"19","author":"Haanes","year":"2018","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/bs.irn.2023.08.001_bib40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bcp.2018.02.002","article-title":"Adenosine metabolism, immunity and joint health","volume":"151","author":"Hask\u00f3","year":"2018","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib41","first-page":"352","article-title":"A2a-Adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: Characterization with radioligand binding and by activation of adenylate cyclase","volume":"41","author":"Hide","year":"1992","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2023.08.001_bib42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.108.149617","volume":"330","author":"Hodgson","year":"2009","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0024-3205(74)90364-6","article-title":"Adenosine-elicited accumulation of cyclic AMP in brain slices: Potentiation by agents which inhibit uptake of adenosine","volume":"14","author":"Huang","year":"1974","journal-title":"Life Sciences"},{"key":"10.1016\/bs.irn.2023.08.001_bib44","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73901","article-title":"Allosteric modulation of the adenosine A2A receptor by cholesterol","volume":"11","author":"Huang","year":"2022","journal-title":"eLife"},{"key":"10.1016\/bs.irn.2023.08.001_bib45","first-page":"47","article-title":"CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity","volume":"251","author":"Hutchison","year":"1989","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2023.08.001_bib46","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","article-title":"International Union of Basic and Clinical Pharmacology. CXII: Adenosine receptors \u2013 A further update","volume":"74","author":"IJzerman","year":"2022","journal-title":"Pharmacological Reviews"},{"issue":"5","key":"10.1016\/bs.irn.2023.08.001_bib47","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial","volume":"14","author":"Iskandrian","year":"2007","journal-title":"Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology"},{"issue":"5905","key":"10.1016\/bs.irn.2023.08.001_bib48","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.irn.2023.08.001_bib49","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1021\/jm00062a005","article-title":"Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists","volume":"36","author":"Jacobson","year":"1993","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.irn.2023.08.001_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.irn.2023.08.001_bib51","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1021\/bc9000596","article-title":"Functionalized congener approach to the design of ligands for G protein\u2013coupled receptors (GPCRs)","volume":"20","author":"Jacobson","year":"2009","journal-title":"Bioconjugate Chemistry"},{"key":"10.1016\/bs.irn.2023.08.001_bib52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fncel.2019.00124","article-title":"Historical and current adenosine receptor agonists in preclinical and clinical development","volume":"13","author":"Jacobson","year":"2019","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/bs.irn.2023.08.001_bib53","first-page":"1","article-title":"Adenosine A2A receptor antagonists: From caffeine to selective non-xanthines","author":"Jacobson","year":"2020","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib54","first-page":"888","article-title":"[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain","volume":"251","author":"Jarvis","year":"1989","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2023.08.001_bib55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/acs.chemrev.6b00119","article-title":"Structurally enabled discovery of adenosine A2A receptor antagonists","volume":"117","author":"Jazayeri","year":"2017","journal-title":"Chemical Reviews"},{"key":"10.1016\/bs.irn.2023.08.001_bib56","first-page":"512","article-title":"Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2a adenosine receptors are required for ligand recognition","volume":"50","author":"Jiang","year":"1996","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2013.07.001","article-title":"A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats","volume":"98","author":"Jones","year":"2013","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/bs.irn.2023.08.001_bib58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0014-2999(94)90551-7","article-title":"A novel selective adenosine A2A antagonist with anticataleptic activity","volume":"256","author":"Kanda","year":"1994","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib59","doi-asserted-by":"crossref","first-page":"13987","DOI":"10.1074\/jbc.270.23.13987","article-title":"Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor","volume":"270","author":"Kim","year":"1995","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.irn.2023.08.001_bib60","first-page":"683","article-title":"Glutamate residues in the second extracellular loop of the human A2a adenosine receptors are required for ligand recognition","volume":"49","author":"Kim","year":"1996","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0000000000000073","article-title":"Japanese Istradefylline Study Group A long-term study of istradefylline safety and efficacy in patients with Parkinson disease","volume":"38","author":"Kondo","year":"2015","journal-title":"Clinical Neuropharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2023.08.001_bib62","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3390\/ijms23042101","article-title":"Allosteric modulation of adenosine A2A receptors as a new therapeutic avenue","volume":"23","author":"Korkutata","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1016\/bs.irn.2023.08.001_bib63","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.bcp.2010.06.041","article-title":"Characterization of [3H]LUF5834: A novel non-ribose high-affinity agonist radioligand for the adenosine A1 receptor","volume":"80","author":"Lane","year":"2010","journal-title":"Biochemical Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib64","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/mol.111.075937","article-title":"A novel nonribose agonist, LUF5834, engages residues that are distinct from those of adenosine-like ligands to activate the adenosine A2a receptor","volume":"81","author":"Lane","year":"2012","journal-title":"Molecular Pharmacology"},{"issue":"7","key":"10.1016\/bs.irn.2023.08.001_bib65","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1517\/13543784.14.7.797","article-title":"Adenosine A2A agonists in development for the treatment of inflammation","volume":"14","author":"Lappas","year":"2005","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"2","key":"10.1016\/bs.irn.2023.08.001_bib66","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/bbrc.1996.0916","article-title":"Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A","volume":"223","author":"Le","year":"1996","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"7352","key":"10.1016\/bs.irn.2023.08.001_bib67","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nature10136","article-title":"Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation","volume":"474","author":"Lebon","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.irn.2023.08.001_bib68","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1124\/mol.114.097360","article-title":"X-ray structure of CGS2680-bound human A2AR","volume":"87","author":"Lebon","year":"2015","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib69","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.parkreldis.2020.10.027","article-title":"The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant","volume":"80","author":"LeWitt","year":"2020","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/bs.irn.2023.08.001_bib70","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1124\/mol.105.011783","article-title":"Adenosine in tissue protection and tissue regeneration","volume":"67","author":"Linden","year":"2005","journal-title":"Molecular Pharmacology"},{"issue":"6091","key":"10.1016\/bs.irn.2023.08.001_bib71","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1126\/science.1219218","article-title":"Structural basis for allosteric regulation of GPCRs by sodium ions","volume":"337","author":"Liu","year":"2012","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.irn.2023.08.001_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114367","article-title":"Use of knockout mice to explore CNS effects of adenosine","volume":"187","author":"Lopes","year":"2021","journal-title":"Biochemical Pharmacology"},{"issue":"6","key":"10.1016\/bs.irn.2023.08.001_bib73","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/acschembio.0c00899","article-title":"Affinity mass spectrometry-based fragment screening identified a new negative allosteric modulator of the adenosine A2A receptor targeting the sodium ion pocket","volume":"16","author":"Lu","year":"2021","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/bs.irn.2023.08.001_bib74","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0006-291X(05)80909-X","article-title":"RDC8 encodes for an adenosine A2 receptor with physiological constitutive activity","volume":"173","author":"Maenhaut","year":"1990","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/bs.irn.2023.08.001_bib75","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/ecp.09.57","article-title":"Design and application of locally delivered agonists of the adenosine A2A receptor","volume":"3","author":"Mantell","year":"2010","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.652455","article-title":"An open question: Is the A2A adenosine receptor a novel target for Alzheimer\u2019s disease treatment?","volume":"12","author":"Merighi","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2023.08.001_bib77","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.3390\/molecules27092680","article-title":"Pathophysiological role and medicinal chemistry of A2A adenosine receptor antagonists in Alzheimer\u2019s disease","volume":"27","author":"Merighi","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/bs.irn.2023.08.001_bib78","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00213-008-1441-z","article-title":"The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost\/benefit procedure","volume":"204","author":"Mott","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib79","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","article-title":"Recent developments in adenosine receptor ligands and their potential as novel drugs","volume":"1808","author":"M\u00fcller","year":"2011","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"key":"10.1016\/bs.irn.2023.08.001_bib80","first-page":"492","article-title":"Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma","volume":"2","author":"Murray","year":"2009","journal-title":"Circulation: Cardiovascular Imaging"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib81","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jphs.2023.05.001","article-title":"The adenosine A2A receptor antagonist\/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets","volume":"152","author":"Ohno","year":"2023","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/bs.irn.2023.08.001_bib82","doi-asserted-by":"crossref","DOI":"10.1124\/molpharm.122.000633","article-title":"In vitro pharmacological profile of KW-6356, a novel adenosine A2A receptor antagonist\/inverse agonist","author":"Ohno","year":"2023","journal-title":"Molecular Pharmacology"},{"issue":"6866","key":"10.1016\/bs.irn.2023.08.001_bib83","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/414916a","article-title":"Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage","volume":"414","author":"Ohta","year":"2001","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib84","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1254\/jjp.78.269","article-title":"Effects of YT-146 [2-(1-octynyl) adenosine], an adenosine A2A receptot agonist, on cAMP production and noradrenaline release in PC12 cells","volume":"78","author":"Ono","year":"1998","journal-title":"Japanese Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib85","first-page":"970","article-title":"125I-4-(2-[7-Amino-2-{furyl}{1,2,4}triazolo{2,3-a}{1,3,5}triazin-5-ylaminoethyl)phenol (125I-ZM241385), a high affinity antagonist radioligand selective for the A2a adenosine receptor","volume":"48","author":"Palmer","year":"1996","journal-title":"Molecular Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/1098-2396(20010301)39:3<233::AID-SYN1004>3.0.CO;2-K","article-title":"Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats","volume":"39","author":"Pinna","year":"2001","journal-title":"Synapse (New York, N. Y.)"},{"issue":"11","key":"10.1016\/bs.irn.2023.08.001_bib87","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/13543780903241615","article-title":"Novel investigational adenosine A2A receptor antagonists for Parkinson\u2019s disease","volume":"18","author":"Pinna","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/bs.irn.2023.08.001_bib88","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1476-5381.1995.tb15923.x","article-title":"The in vitro pharmacology of ZM241385, a potent, non-xanthine, A2a selective adenosine receptor antagonist","volume":"115","author":"Poucher","year":"1995","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2023.08.001_bib89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1021\/jm00177a021","article-title":"Modification of the 5\u2032 position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5\u2032-(N-substituted)carboxamides.","volume":"23","author":"Prasad","year":"1980","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/bs.irn.2023.08.001_bib90","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/med.21344","article-title":"History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents","volume":"35","author":"Preti","year":"2015","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/bs.irn.2023.08.001_bib91","first-page":"22","article-title":"Adenosine A2A receptor binding profile of two antagonists, ST1535 and KW6002: Consideration on the presence of atypical adenosine A2A binding sites","volume":"1","author":"Riccioni","year":"2010","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/bs.irn.2023.08.001_bib92","unstructured":"Rosentreter, U., Henning, R., Bauser, M., Kr\u00e4mer, T., Vaupel, A., H\u00fcbsch, W., ... Krahn T. Substituted 2-Thio-3,5-Dicyano-4-Aryl-6-Aminopyridines and the Use Thereof as Adenosine Receptor Ligands. WO2001025210."},{"key":"10.1016\/bs.irn.2023.08.001_bib93","doi-asserted-by":"crossref","unstructured":"Salmaso, V., Jain, S., Jacobson, K.A. (2021). Purinergic GPCR transmembrane residues involved in ligand recognition and dimerization. In A. Shukla, Ed., Meth. Cell Biol, 166, (pp. 133\u2013159). Biomolecular Interactions. https:\/\/doi.org\/10.1016\/bs.mcb.2021.06.001.","DOI":"10.1016\/bs.mcb.2021.06.001"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib94","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/jm1008659","article-title":"Discovery of phosphoric acid mono-{2-[(E\/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist","volume":"54","author":"Sams","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.irn.2023.08.001_bib95","first-page":"13","article-title":"The effect of adenosine and adenine nucleotides on the cyclic adenosine 3\u2032, 5\u2032-phosphate content of guinea pig cerebral cortex slices","volume":"6","author":"Sattin","year":"1970","journal-title":"Molecular Pharmacology"},{"issue":"5","key":"10.1016\/bs.irn.2023.08.001_bib96","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","article-title":"Adenosine A2A receptors and basal ganglia physiology","volume":"83","author":"Schiffmann","year":"2007","journal-title":"Progress in Neurobiology"},{"issue":"2","key":"10.1016\/bs.irn.2023.08.001_bib97","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2222.1982.tb01641.x","article-title":"The clinical and pharmacological history of theophylline: first report on the bronchospasmolytic action in man by S. R. Hirsch in Frankfurt (Main) 1922","volume":"12","author":"Schultze-Werninghaus","year":"1982","journal-title":"Clinical Allergy"},{"key":"10.1016\/bs.irn.2023.08.001_bib98","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2174\/138161212799436430","article-title":"Multi-parameter optimization: Identifying high quality compounds with a balance of properties","volume":"18","author":"Segall","year":"2012","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/bs.irn.2023.08.001_bib99","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","article-title":"Impact of the selective A2AR and A2BR dual antagonist AB928\/etrumadenant on CAR T cell function","volume":"127","author":"Seifert","year":"2022","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1016\/bs.irn.2023.08.001_bib100","first-page":"6325","article-title":"GPCR agonist-to-antagonist conversion: Enabling the design of nucleoside functional switches for the A2A adenosine receptor","volume":"65","author":"Shiriaeva","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.irn.2023.08.001_bib101","doi-asserted-by":"crossref","first-page":"1120532","DOI":"10.3389\/fncel.2023.1120532","article-title":"The adenosine hypothesis of schizophrenia into its thirddecade: From neurochemical imbalance to early life etiological risks","volume":"17","author":"Singer","year":"2023","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/bs.irn.2023.08.001_bib102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejphar.2014.01.052","article-title":"Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice","volume":"728","author":"Smith","year":"2014","journal-title":"European Journal of Pharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2023.08.001_bib103","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.3390\/molecules27082386","article-title":"A2A adenosine receptor antagonists: Are triazolotriazine and purine scaffolds interchangeable?","volume":"27","author":"Spinaci","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"key":"#cr-split#-10.1016\/bs.irn.2023.08.001_bib104.1","unstructured":"Stein, H. H., Prasad, R. N., & Tietje, K. R. (1979). Adenosine-5\u2032-carboxamides for controlling undesired animals. US 4,167, 565"},{"key":"#cr-split#-10.1016\/bs.irn.2023.08.001_bib104.2","unstructured":"(1980). Chemical Abstracts, 92,\u00a0P76890."},{"key":"10.1016\/bs.irn.2023.08.001_bib105","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1021\/jm0009843","article-title":"Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A2A receptor system using positron emission tomography","volume":"43","author":"Todde","year":"2000","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.irn.2023.08.001_bib106","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1021\/jm00108a014","article-title":"2-Alkoxyadenosines: Potent and selective agonists at the coronary artery A2 adenosine receptor","volume":"34","author":"Ueeda","year":"1991","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.irn.2023.08.001_bib107","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cmdc.201600219","article-title":"Synthesis and in vivo evaluation of Fluorine-18 and Iodine-123 Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as PET and SPECT radiotracers for mapping A2A receptors","volume":"11","author":"Vala","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/bs.irn.2023.08.001_bib108","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/jm010952v","article-title":"2,5\u2032-Disubstituted adenosine derivatives: Evaluation of selectivity and efficacy for the adenosine A1, A2A, and A3 receptor","volume":"45","author":"van Tilburg","year":"2002","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.irn.2023.08.001_bib109","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2023.08.001_bib110","doi-asserted-by":"crossref","first-page":"625134","DOI":"10.3389\/fphar.2020.625134","article-title":"A1 Adenosine receptor partial agonists and allosteric modulators: Advancing toward the clinic?","volume":"11","author":"Vincenzi","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/bs.irn.2023.08.001_bib111","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1016\/j.bmc.2006.01.011","article-title":"Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl) caffeine (CSC)","volume":"14","author":"Vlok","year":"2006","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/bs.irn.2023.08.001_bib112","doi-asserted-by":"crossref","first-page":"1027838","DOI":"10.3389\/fimmu.2022.1027838","article-title":"Adenosine signaling: Optimal target for gastric cancer immunotherapy","volume":"13","author":"Wang","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2023.08.001_bib113","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/molecules25010130","article-title":"Adenosine receptor agonists exhibit anti-platelet effects and the potential to overcome resistance to P2Y12 receptor antagonists","volume":"25","author":"Wolska","year":"2020","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"3","key":"10.1016\/bs.irn.2023.08.001_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000161","article-title":"Physiology and effects of nucleosides in mice lacking all four adenosine receptors","volume":"17","author":"Xiao","year":"2019","journal-title":"PLoS Biology"},{"issue":"9","key":"10.1016\/bs.irn.2023.08.001_bib115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/ph13090237","article-title":"Tumor immunotherapy using A2A adenosine receptor antagonists","volume":"13","author":"Zhang","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"16","key":"10.1016\/bs.irn.2023.08.001_bib116","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.89.16.7432","article-title":"Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor","volume":"89","author":"Zhou","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"}],"container-title":["International Review of Neurobiology","Adenosine A2A Receptor Antagonists"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774223000788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774223000788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T19:41:01Z","timestamp":1698694861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774223000788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443186677"],"references-count":117,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2023.08.001","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}